Labiotech.eu

News and Trends 13 Sep 2022

Ilya Pharma partners with US Defense Department for wound healing drug

A drug to accelerate wound healing and reduced scar volume has had a major breakthrough shown in results from a first in human trial. Ilya Pharma, a clinical stage immunotherapy company presented the findings at the US Defense Department’s (DoD) Military Health System Research Symposium (MHSRS) Conference in Florida and made the announcement yesterday (September […]

September 13, 2022 - 3 minutesmins - By Liza Laws

Optics11 Life receives €5 million in funding for drug development

News and Trends 13 Sep 2022

Arpeggio Biosciences raises $17M in Series A funding to support drug pipeline

Arpeggio Biosciences has raised $17 million in series A funding in a round led by Builders VC. Support for the U.S.-based preclinical therapeutics company making technology targeting transcriptional dysregulation in disease, also came from its seed round investors. These include Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, as well as new participants […]

September 13, 2022 - 2 minutesmins - By Liza Laws

News and Trends 13 Sep 2022

Starpharma announces new data for prostate cancer trial

Cabazitaxel (Jevtana, Sanofi) is a chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel that has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. In a poster presentation at ESMO […]

September 13, 2022 - 2 minutesmins - By Jim Cornall

More News! 13 Sep 2022

Research charity calls on scientists, engineers, and technology experts to transform dialysis treatment

Following its successful MedTech competition earlier this year, the UK’s largest kidney research charity, Kidney Research UK, has launched a new competition aimed at innovations in dialysis that will have a significant impact on patients’ lives. In collaboration with IN-PART’s Discover platform, this year’s competition will encourage scientists, academics, engineers and technology experts to propose […]

September 13, 2022 - 3 minutesmins - By External Contributor

News and Trends 13 Sep 2022

Himalaya Therapeutics publishes data on cancer treatment

Himalaya Therapeutics has given an interim topline data update from its phase 2 study of HTBA3011 (mecbotamab vedotin) in non-small cell lung cancer (NSCLC) and certain sarcomas. In August, Himalaya’s collaboration partner, BioAtla publicly announced operational updates on the ongoing global clinical trials for HTBA3011 in patients with AXL-positive NSCLC who have previously failed PD-1/L1, […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Sep 2022

Aldatu gets grant to develop Crimean Congo hemorrhagic fever test

U.S. biotech company Aldatu Biosciences has been awarded a $3 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the advancement of the company’s proprietary PANDAA technology platform and its specific application to the […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Sep 2022

Scope Biosciences and WUR to improve CRISPR-Cas technology with new funds

Wageningen University & Research (WUR), and its spinoff Scope Biosciences, have received a grant of €150,000 ($152,000) from the European Research Council (ERC). The grant is to further research and enhance the diagnostic technology ScopeDx. This is based on CRISPR-Cas technology. Uniquely, this technology is able to quickly and accurately recognize viral or bacterial RNA. […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

PDC*line Pharma presents results from phase I/II trial

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, has revealed the first results of its PDC-LUNG-101 phase I/II clinical trial with PDC*lung01. PDC*lung01 is the company’s therapeutic off-the shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). The preliminary data was presented at […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Enterome presents more data on therapeutic cancer treatment

Clinical stage biopharma company Enterome has presented new data from its two phase 1/2 clinical trials of its OncoMimics cancer immunotherapy EO2401. The trails are in combination with nivolumab (Opdivo) +/- bevacizumab (Avastin), in patients with first progression/recurrence of glioblastoma (ROSALIE trial), and in combination with nivolumab in patients with non-resectable adrenocortical carcinomas (ACC) and […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Astellas, Seagen and Merck give details on urothelial cancer treatment

Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […]

September 12, 2022 - 5 minutesmins - By Jim Cornall

Interview 12 Sep 2022

Orchestrating the evolving cell therapy supply chain

In a few decades, the cell and gene therapy sector has diversified into many complex technologies. Paul Viggers, chief commercial officer at the U.K. firm TrakCel, explains how the company’s platform can tackle the intricacies of developing cell and gene therapies. After cell and gene therapy funding smashed records in 2021, the emerging sector has […]

September 12, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 12 Sep 2022

Treatment for adults with moderate to severe psoriasis approved by FDA

A treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been approved by the U.S. Food and Drug Administration (FDA). Bristol Myers Squibb made the announcement today (September 12) that its allosteric tyrosine kinase 2 (TYK2) inhibitor, Sotyku (deucravacitinib) had been approved based on results from a phase […]

September 12, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ilya Pharma partners with US Defense Department for wound healing drug

Arpeggio Biosciences raises $17M in Series A funding to support drug pipeline

Starpharma announces new data for prostate cancer trial

Research charity calls on scientists, engineers, and technology experts to transform dialysis treatment

Himalaya Therapeutics publishes data on cancer treatment

Aldatu gets grant to develop Crimean Congo hemorrhagic fever test

Scope Biosciences and WUR to improve CRISPR-Cas technology with new funds

PDC*line Pharma presents results from phase I/II trial

Enterome presents more data on therapeutic cancer treatment

Astellas, Seagen and Merck give details on urothelial cancer treatment

Orchestrating the evolving cell therapy supply chain

Treatment for adults with moderate to severe psoriasis approved by FDA

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!